|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Differences between main-duct and branch-duct intraductal papillary mucinous neoplasms of the pancreas显示文摘In the last decade,intraductal papillary mucinous neoplasms(IPMNs) have become commonly diagnosed.From a morphological standpoint,they are classified in main-duct IPMNs(MD-IPMNs) and branch-duct IPMNs(BD-IPMNs),depending on the type of involvement of the pancreatic ductal system by the neoplasm.Despite the fact that our understanding of their natural history is still incomplete,recent data indicate that MD-IPMNs and BD-IPMNs show significant differences in terms of biological behaviour with MD-IPMNs at higher risk of malignant degeneration.In the present paper,clinical and epidemiological characteristics,rates of malignancy and the natural history of MD-IPMNs and BD-IPMNs are analyzed.The profile of IPMNs involving both the main pancreatic duct and its side branches(combined-IPMNs) are also discussed.Finally,general recommendations for management based on these differences are given. | Roberto Salvia Stefano Crippa Stefano Partelli Giulia Armatura Giuseppe Malleo Marina Paini Antonio Pea Claudio Bassi | 2010 | World Journal of Gastrointestinal Surgery2010，2，10： | 14 |
| 2 | Enhanced Photoprotection by Protein-Bound vs Free Xanthophyll Pools: A Comparative Analysis of Chlorophyll b and Xanthophyll Biosynthesis Mutants显示文摘当植物吸收的光超过光合作用的能力时,黄色色素 violaxanthin 是 reversibly de-epoxidized 到在所谓的黄色色素周期的玉米黄质。玉米黄质迎着过量光在光合的有机体的保护起一个关键作用,由支持很快可逆(qE ) 并且长期(qI ) 激动的叶绿素熄灭,并且阻止类脂化合物氧化。玉米黄质,免费的任何一个或到轻收获的建筑群(Lhcs ) 的界限的 photoprotective 角色,被使用缺乏 Chl b (ch1 ) 或特定的黄色色素种类的异种调查了(npq, lut2 ) 。ch1 变化原因(1 ) Lhcb 蛋白质的缺席;(2 ) 反馈 de 刺激(qE ) 的强壮的减小;并且(3 ) 是的黄色色素的累积免费颜料进 thylakoids。Ch1 异种在高光显示出极端敏感到相片氧化的应力,由于更高的汗衫氧(1O2 ) 版本。双变异的 ch1npq1 比 ch1 对相片氧化更敏感,证明甚至当时,那玉米黄质确实保护类脂化合物在膜免费。不过,玉米黄质的缺乏在包含 Lhcs 植物(WT 对 npq1 ) 有类脂化合物 peroxidation 诚实的强壮得多的影响关于 Lhc 少些种(ch1 对 ch1npq1 ) ,暗示它的保护的效果被和天线蛋白质的相互作用提高。玉米黄质的抗氧化剂能力面对 PSIILHCsZea 建筑群被授权,这被建议,当它 qE 的改进上的效果仅仅提供次要的贡献时。到外长的 1O2 的 WT 对 npq1 植物的敏感的比较建议除 1O2 清除以外,至少一另外的机制涉及叶绿体 photoprotection。 | Luca Dall'Osto Stefano Cazzaniga Michel Havaux Roberto Bassi | 2010 | Molecular Plant2010，3，3： | 8 |
| 3 | Percutaneous ablation of pancreatic cancer显示文摘Pancreatic ductal adenocarcinoma is a highly aggressive tumor with an overall 5-year survival rate of less than 5%. Prognosis and treatment depend on whether the tumor is resectable or not, which mostly depends on how quickly the diagnosis is made. Chemotherapy and radiotherapy can be both used in cases of nonresectable pancreatic cancer. In cases of pancreatic neoplasm that is locally advanced, non-resectable, but non-metastatic, it is possible to apply percutaneous treatments that are able to induce tumor cytoreduction. The aim of this article will be to describe the multiple currently available treatment techniques(radiofrequency ablation, microwave ablation, cryoablation, and irreversible electroporation), their results, and their possible complications, with the aid of a literature review. | Mirko D'Onofrio Valentina Ciaravino Riccardo De Robertis Emilio Barbi Roberto Salvia Roberto Girelli Salvatore Paiella Camilla Gasparini Nicolò Cardobi Claudio Bassi | 2016 | World Journal of Gastroenterology2016，22，44： | 7 |
| 4 | Radiofrequency ablation of locally advanced pancreatic adenocarcinoma:An overview显示文摘Radiofrequency ablation(RFA)of pancreatic neoplasms is restricted to locally advanced,non-resectable but nonmetastatic tumors.RFA of pancreatic tumors is nowadays an ultrasound-guided procedure performed during laparotomy in open surgery.Intraoperative ultrasound covers the mandatory role of staging,evaluation of feasibility,guidance and monitoring of the procedure.Different types of needle can be used.The first aim in the evaluation of RFA as a treatment for locally advanced pancreatic ductal adenocarcinoma,in order of evaluation but not of importance,is to determine the feasibility of the procedure.The second aim is to establish the effect of RFA on tumoral mass in terms of necrosis andcytoreduction.The most important aim,third in order of evaluation,is the potential improvement of quality of life and survival rate.Nowadays,only a few studies assess the feasibility of the procedure.The present paper is an overview of RFA for pancreatic adenocarcinoma. | Mirko D’Onofrio Emilio Barbi Roberto Girelli Enrico Martone Anna Gallotti Roberto Salvia Paolo Tinazzi Martini Claudio Bassi Paolo Pederzoli Roberto Pozzi Mucelli | 2010 | World Journal of Gastroenterology2010，16，28： | 6 |
| 5 | Early Versus Late Drain Removal After Standard Pancreatic Resections: Results of a Prospective Randomized Trial显示文摘 | Claudio Bassi Enrico Molinari Giuseppe Malleo Stefano Crippa Giovanni Butturini Roberto Salvia Giorgio Talamini Paolo Pederzoli | 2010 | Annals of Surgery2010，，2： | 5 |
| 6 | Pancreaticoduodenectomy in patients ≥ 75 years of age:Are there any differences with other age ranges in oncological and surgical outcomes? Results from a tertiary referral center显示文摘AIM To compare surgical and oncological outcomes after pancreaticoduodenectomy(PD) in patients ≥ 75 years of age with two younger cohorts of patients. METHODS The prospectively maintained Institutional database of pancreatic resection was queried for patients aged ≥ 75 years(late elderly, LE) submitted to PD for any disease from January 2010 to June 2015. We compared clinical, demographic and pathological features and survival outcomes of LE patients with 2 exact matched cohorts of younger patients [≥ 40 to 64 years of age(adults, A) and ≥ 65 to 74 years of age(young elderly, YE)] submitted to PD, according to selected variables. RESULTS The final LE population, as well as the control groups, were made of 96 subjects. Up to 71% of patients was operated on for a periampullary malignancy and pancreatic cancer(PDAC) accounted for 79% of them. Intraoperative data(estimated blood loss and duration of surgery) did not differ among the groups. The overall complication rate was 65.6%, 61.5% and 58.3% for LE, YE and A patients, respectively, P = NS). Reoperation and cardiovascular complications were significantly more frequent in LE than in YE and A groups(P = 0.003 and P = 0.019, respectively). When considering either all malignancies and PDAC only, the three groups did not differ in survival. Considering all benign diseases, the estimated mean survival was 58 and 78 mo for ≥ and < 75 years of age(YE + A groups), respectively(P = 0.012). CONCLUSION Age is not a contraindication for PD. A careful selection of LE patients allows to obtain good surgical and oncological results. | Salvatore Paiella Matteo De Pastena Tommaso Pollini Giovanni Zancan Debora Ciprani Giulia De Marchi Luca Landoni Alessandro Esposito Luca Casetti Giuseppe Malleo Giovanni Marchegiani Massimiliano Tuveri Enrico Marrano Laura Maggino Erica Secchettin Deborah Bonamini Claudio Bassi Roberto Salvia | 2017 | World Journal of Gastroenterology2017，23，17： | 2 |
| 7 | Targeted next‐generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas显示文摘 | Eliana Amato Marco dal Molin Andrea Mafficini Jun Yu Giuseppe Malleo Borislav Rusev Matteo Fassan Davide Antonello Yoshihiko Sadakari Paola Castelli Giuseppe Zamboni Anirban Maitra Roberto Salvia Ralph H Hruban Claudio Bassi Paola Capelli Rita T Lawlor Mi | 2014 | J. Pathol2014，，3： | 2 |
| 8 | Mucin-Producing Neoplasms of the Pancreas: An Analysis of Distinguishing Clinical and Epidemiologic Characteristics显示文摘 | Stefano Crippa Carlos Fernández–del Castillo Roberto Salvia Dianne Finkelstein Claudio Bassi Ismael Domínguez Alona Muzikansky Sarah P. Thayer Massimo Falconi Mari Mino–Kenudson Paola Capelli Gregory Y. Lauwers Stefano Partelli Paolo Pederzoli Andrew L. W | 2010 | Clinical Gastroenterology and Hepatology2010，，2： | 2 |
| 9 | Clinicopathological Correlates of Activating GNAS Mutations in Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas显示文摘 | Marco Dal Molin Hanno Matthaei Jian Wu Amanda Blackford Marija Debeljak Neda Rezaee Christopher L. Wolfgang Giovanni Butturini Roberto Salvia Claudio Bassi Michael G. Goggins Kenneth W. Kinzler Bert Vogelstein James R. Eshleman Ralph H. Hruban Anirban Mai | 2013 | Annals of Surgical Oncology2013，，12： | 2 |
| 10 | Incidence of cancer in the course of chronic pancreatitis显示文摘 | Giorgio Talamini Massimo Falconi Claudio Bassi Nora Sartori Roberto Salvia Erminia Caldiron Luca Frulloni Vincenzo Di Francesco Bruna Vaona Paolo Bovo Italo Vantini Paolo Pederzoli Giorgio Cavallini | 1999 | The American Journal of Gastroenterology1999，，5： | 2 |
| 11 | Efficacy of an Absorbable Fibrin Sealant Patch (TachoSil) After Distal Pancreatectomy: A Multicenter, Randomized, Controlled Trial显示文摘 | Marco Montorsi Alessandro Zerbi Claudio Bassi Lorenzo Capussotti Roberto Coppola Matteo Sacchi | 2012 | Annals of Surgery2012，，5： | 1 |
| 12 | Duct-to-mucosa versus end-to-side pancreaticojejunostomy reconstruction after pancreaticoduodenectomy: results of a prospective randomized trial显示文摘 | Claudio Bassi Massimo Falconi Enrico Molinari William Mantovani Giovanni Butturini Andrew A Gumbs Roberto Salvia Paolo Pederzoli | 2003 | Surgery2003，，5： | 1 |
| 13 | Circulating IGF-I and IGFBP3 Levels Control Human Colonic Stem Cell Function and Are Disrupted in Diabetic Enteropathy显示文摘 | Francesca D’Addio Stefano La Rosa Anna Maestroni Peter Jung Elena Orsenigo Moufida Ben Nasr Sara Tezza Roberto Bassi Giovanna Finzi Alessandro Marando Andrea Vergani Roberto Frego Luca Albarello Annapaola Andolfo Roberta Manuguerra Edi Viale Carlo Staudac | 2015 | Cell Stem Cell2015，，4： | 1 |
| 14 | Triple approach strategy for patients with locally advanced pancreatic carcinoma显示文摘 | Alessandro Giardino Roberto Girelli Isabella Frigerio Paolo Regi Maurizio Cantore Auriemma Alessandra Annita Lusenti Roberto Salvia Claudio Bassi Paolo Pederzoli | 2013 | HPB2013，，8： | 1 |
| 15 | Appraisal of the surgical management for pancreatic serous cystic neoplasms显示文摘 | Giuseppe Malleo Claudio Bassi Roberto Salvia | 2013 | Surgical Endoscopy2013，，7： | 1 |
| 16 | The value of standard serum tumor markers in differentiating mucinous from serous cystic tumors of the pancreas: CEA, Ca 19-9, Ca 125, Ca 15-3显示文摘 | Claudio Bassi Roberto Salvia Andrew A. Gumbs Giovanni Butturini Massimo Falconi Paolo Pederzoli | 2002 | Langenbeck’s Archives of Surgery (-)2002，，7： | 1 |
| 17 | Perioperative management of patients undergoing pancreatic resection: Implementation of a care plan in a tertiary‐care center显示文摘 | Roberto Salvia Giuseppe Malleo Giovanni Butturini Marco Dal Molin Alessandro Esposito Giovanni Marchegiani Salvatore Paiella Anna Malpaga Martina Fontana Beatrice Personi Claudio Bassi | 2012 | J Surg Oncol2012，，1： | 1 |
| 18 | Pancreaticojejunostomy after pancreaticoduodenectomy: Suture material and incidence of post-operative pancreatic fistula显示文摘 | Stefano Andrianello Antonio Pea Alessandra Pulvirenti Valentina Allegrini Giovanni Marchegiani Giuseppe Malleo Giovanni Butturini Roberto Salvia Claudio Bassi | 2015 | Pancreatology2015，，： | 1 |
| 19 | Computed tomography-based radiomic to predict resectability in locally advanced pancreatic cancer treated with chemotherapy and radiotherapy显示文摘BACKGROUND Surgical resection after neoadjuvant treatment is the main driver for improved survival in locally advanced pancreatic cancer(LAPC).However,the diagnostic performance of computed tomography(CT)imaging to evaluate the residual tumour burden at restaging after neoadjuvant therapy is low due to the difficulty in distinguishing neoplastic tissue from fibrous scar or inflammation.In this context,radiomics has gained popularity over conventional imaging as a complementary clinical tool capable of providing additional,unprecedented information regarding the intratumor heterogeneity and the residual neoplastic tissue,potentially serving in the therapeutic decision-making process.AIM To assess the capability of radiomic features to predict surgical resection in LAPC treated with neoadjuvant chemotherapy and radiotherapy.METHODS Patients with LAPC treated with intensive chemotherapy followed by ablative radiation therapy were retrospectively reviewed.One thousand six hundred and fifty-five radiomic features were extracted from planning CT inside the gross tumour volume.Both extracted features and clinical data contribute to create and validate the predictive model of resectability status.Patients were repeatedly divided into training and validation sets.The discriminating performance of each model,obtained applying a LASSO regression analysis,was assessed with the area under the receiver operating characteristic curve(AUC).The validated model was applied to the entire dataset to obtain the most significant features.RESULTS Seventy-one patients were included in the analysis.Median age was 65 years and 57.8%of patients were male.All patients underwent induction chemotherapy followed by ablative radiotherapy,and 19(26.8%)ultimately received surgical resection.After the first step of variable selections,a predictive model of resectability was developed with a median AUC for training and validation sets of 0.862(95%CI:0.792-0.921)and 0.853(95%CI:0.706-0.960),respectively.The validated model was applied to the entire dataset and 4 features were selected to build the model with predictive performance as measured using AUC of 0.944(95%CI:0.892-0.996).CONCLUSION The present radiomic model could help predict resectability in LAPC after neoadjuvant chemotherapy and radiotherapy,potentially integrating clinical and morphological parameters in predicting surgical resection. | Gabriella Rossi Luisa Altabella Nicola Simoni Giulio Benetti Roberto Rossi Martina Venezia Salvatore Paiella Giuseppe Malleo Roberto Salvia Stefania Guariglia Claudio Bassi Carlo Cavedon Renzo Mazzarotto | 2022 | World Journal of Gastrointestinal Oncology2022，14，3： | 1 |
| 20 | Prophylaxis for septic complications in acute necrotizing pancreatitis显示文摘 | Claudio Bassi Gerardo Mangiante Massimo Falconi Roberto Salvia Isabella Frigerio Paolo Pederzoli | 2001 | Journal of Hepato - Biliary - Pancreatic Surgery2001，，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员